Mycophenolate Mofetil in Systemic Sclerosis With Subclinical Interstitial Lung Disease
Status:
Not yet recruiting
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
The goal of this pilot study is to assess the feasibility of a larger study on the efficacy
of mycophenolate mofetil in people diagnosed with systemic sclerosis with mild lung
involvement. Participants will be recruited over 12 months at 3 academic centers and assigned
randomly to receive either mycophenolate mofetil or placebo, a look-alike substance that
contains no active drug, for 96 weeks.
Phase:
Phase 2
Details
Lead Sponsor:
Centre hospitalier de l'Université de Montréal (CHUM)
Collaborators:
Canadian Institutes of Health Research (CIHR) Jewish General Hospital McGill University Sclérodermie Québec St. Joseph's Healthcare Hamilton University of Calgary